Investigation Report on China Sevoflurane Market, 2010-2019
Sevoflurane is an inhalational anaesthetic for maintenance of general anesthesia with the fastest onset and offset. And it not only has little influence on circulation, liver and kidney functions but also protects cardiac muscles. Therefore, sevoflurane has become the main inhaled anaesthetic which is especially fit for patients with myocardial damage. Anaesthetic is divided into local and general anaesthetic with the latter dominating the market.
In 1996, Ultane of Abbott entered China, followed by Sevorane of Maruishi and Sevoflurane of Baxter Healthcare Corporation. In 2007 and 2008 respectively, inhaled solution of sevoflurane made by Shanghai Hengrui Pharmaceutical and Lunan Better Pharmaceutical were approved by CFDA to enter the market too.
According to the Chinese government’s statistics, the number of hospitalized cases rose from 115 million in 2008 to 192 million in 2013, among which a quarter need operations. And CAGR during this period exceeded 8%. Therefore it is clear to see that as operations rise in number, the demand for anaesthetics will rise too.
According to CRI’s market survey, the sales value of sevoflurane in sample hospitals rose from less than CNY 4 million in 2005 to over CNY 400 million in 2014 with CAGR during this period reaching 71%.
According to CRI’s market survey, MARUISHI PHARMACEUTICAL CO.,LTD.(JA), Shanghai Hengrui Pharmaceutical Co., Ltd, BAXTER HEALTHCARE CORPORATION(US), Jiangsu Hengrui Medicine Co., Ltd and MARUKO(JA) occupy the market, among which MARUISHI PHARMACEUTICAL CO.,LTD.(JA) had the largest market share of about 41% for sales value in 2014.
As the demand for anaesthetic keeps rising as a result of increasing operations, sevoflurane enjoys good market prospects.
Readers can get at least the following information through this report:
market size of sevoflurane in China
competitive landscape of sevoflurane market in China
price of sevoflurane made by different enterprises in China
market outlook of sevoflurane in China
The author suggests the following groups of people purchase this report:
investors/research institutions interested in Chinese medicine market
-any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed